Retrophin Company Profile (NASDAQ:RTRX)

About Retrophin (NASDAQ:RTRX)

Retrophin logoRetrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RTRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $915.87 million
  • Outstanding Shares: 38,385,000
Average Prices:
  • 50 Day Moving Avg: $20.41
  • 200 Day Moving Avg: $19.18
  • 52 Week Range: $15.55 - $24.57
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.12
  • P/E Growth: -1.05
Sales & Book Value:
  • Annual Revenue: $143.69 million
  • Price / Sales: 6.37
  • Book Value: $7.73 per share
  • Price / Book: 3.09
  • EBIDTA: ($24,860,000.00)
  • Net Margins: -48.74%
  • Return on Equity: -7.31%
  • Return on Assets: -4.27%
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 4.01%
  • Quick Ratio: 3.96%
  • Average Volume: 299,939 shs.
  • Beta: 1.11
  • Short Ratio: 21.8

Frequently Asked Questions for Retrophin (NASDAQ:RTRX)

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin, Inc. (NASDAQ:RTRX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.10. The firm had revenue of $38.80 million for the quarter, compared to the consensus estimate of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The company's quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.07 EPS. View Retrophin's Earnings History.

Where is Retrophin's stock going? Where will Retrophin's stock price be in 2017?

4 equities research analysts have issued 1-year target prices for Retrophin's stock. Their forecasts range from $28.00 to $45.00. On average, they expect Retrophin's stock price to reach $35.00 in the next twelve months. View Analyst Ratings for Retrophin.

What are analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:

  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (5/3/2017)
  • 2. BMO Capital Markets analysts commented, "We maintain our Outperform rating on RTRX shares following Retrophin's announcement to initiate a Phase III trial in 2H17 for Sparsentan. Our price target decreases to $45 from $46, as we push back Sparsentan estimates by two years, but increase our probability of success to 75% from 55%. We believe FDA agreement for proteinuria as an approvable endpoint removes significant uncertainty around Sparsentan's regulatory path as well as avoids a lengthy trial requiring eGFR or kidney survival as endpoints. We estimate Sparsentan peak sales (US only) of $1bn." (3/2/2017)

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:

  • Gary A. Lyons, Independent Chairman of the Board
  • Stephen J. Aselage, President, Chief Executive Officer, Director
  • Laura M. Clague CPA, Chief Financial Officer, Senior Vice President
  • Neil McFarlane, Chief Operating Officer
  • Elizabeth E. Reed, Senior Vice President, General Counsel and Corporate Secretary
  • William E. Rote Ph.D., Senior Vice President and Head of Research and Development
  • Roy D. Baynes M.D. Ph.D., Independent Director
  • Timothy P. Coughlin CPA, Independent Director
  • John W. Kozarich, Independent Director
  • Jeffrey A. Meckler, Independent Director

Who owns Retrophin stock?

Retrophin's stock is owned by many different of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (7.46%), FMR LLC (4.98%), Jennison Associates LLC (4.45%), Vanguard Group Inc. (4.28%), Macquarie Group Ltd. (3.10%) and State Street Corp (3.10%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Jensen Margaret E Valeur, Neil F Mcfarlane and Steve Aselage. View Institutional Ownership Trends for Retrophin.

Who sold Retrophin stock? Who is selling Retrophin stock?

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Numeric Investors LLC, Jennison Associates LLC, FMR LLC, OxFORD Asset Management LLP, Broadfin Capital LLC, Tudor Investment Corp ET AL and State Street Corp. Company insiders that have sold Retrophin stock in the last year include Alvin Shih, Neil F Mcfarlane and Steve Aselage. View Insider Buying and Selling for Retrophin.

Who bought Retrophin stock? Who is buying Retrophin stock?

Retrophin's stock was acquired by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Dimensional Fund Advisors LP, Macquarie Group Ltd., Vanguard Group Inc., PDT Partners LLC, Emory University, Schwab Charles Investment Management Inc. and Alliancebernstein L.P.. View Insider Buying and Selling for Retrophin.

How do I buy Retrophin stock?

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of Retrophin stock can currently be purchased for approximately $23.86.

MarketBeat Community Rating for Retrophin (NASDAQ RTRX)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.00 (46.69% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/2/2017BMO Capital MarketsLower Price TargetOutperform$46.00 -> $45.00N/AView Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/AView Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00N/AView Rating Details
(Data available from 8/20/2015 forward)


Earnings History for Retrophin (NASDAQ:RTRX)
Earnings by Quarter for Retrophin (NASDAQ:RTRX)
Earnings History by Quarter for Retrophin (NASDAQ RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.24)($0.34)$37.36 million$38.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.22)$0.01$36.20 million$33.62 millionViewListenView Earnings Details
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.23 million$17.37 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)$8.35 millionViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Retrophin (NASDAQ:RTRX)
2017 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.19)($0.22)
Q2 20172($0.25)($0.19)($0.22)
Q3 20172($0.28)($0.18)($0.23)
Q4 20172($0.30)($0.17)($0.24)
(Data provided by Zacks Investment Research)


Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Retrophin (NASDAQ:RTRX)
Insider Ownership Percentage: 2.41%
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Neil F McfarlaneCOOSell1,378$22.50$31,005.00View SEC Filing  
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Retrophin (NASDAQ:RTRX)
Latest Headlines for Retrophin (NASDAQ:RTRX)
DateHeadline logoRetrophin, Inc. (RTRX) COO Sells $31,005.00 in Stock - August 17 at 10:48 PM logoRetrophin, Inc. (RTRX) Rating Increased to Buy at BidaskClub - August 16 at 2:41 PM logoRetrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nasdaq - August 14 at 8:34 PM logoRetrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 14 at 8:34 PM logoRetrophin, Inc. (RTRX) Expected to Post Quarterly Sales of $39.02 Million - August 14 at 1:18 AM logoRetrophin, Inc. (RTRX) Given Average Recommendation of "Buy" by Brokerages - August 13 at 12:32 AM logoSentencing Is When Martin Shkreli's Antics Will Come Back To Haunt Him - August 12 at 7:31 AM logoRetrophin, Inc. (RTRX) Announces Quarterly Earnings Results, Misses Expectations By $0.10 EPS - August 11 at 8:55 PM logoInvestor Network: Retrophin, Inc. to Host Earnings Call - August 10 at 7:35 AM logoRetrophin Reports Second Quarter 2017 Financial Results - August 10 at 7:35 AM logoRetrophin reports 2Q loss - August 10 at 7:35 AM logoEdited Transcript of RTRX earnings conference call or presentation 9-Aug-17 8:30pm GMT - August 10 at 7:35 AM logoShkreli's Delight and Crypto Karma - August 8 at 6:48 AM logoShkreli sentence turns on antics, investor impact of crime - August 7 at 1:41 AM logoRetrophin, Inc. (RTRX) Raised to Hold at ValuEngine - August 6 at 10:02 AM logoMartin Shkreli on verdict: This was a witch hunt of epic ... - August 6 at 5:10 AM logoMartin Shkreli Found Guilty On 3 Counts, Including Securities Fraud - August 6 at 5:10 AM logoShkreli Convicted of Securities Fraud by U.S. Jury - August 6 at 5:10 AM logo'Pharma Bro' Martin Shkreli Reacts to Fraud Conviction - August 6 at 5:10 AM logoWhy ‘Pharma Bro’ Martin Shkreli Is Swaggering Into Jail - August 6 at 5:10 AM logoMartin Shkreli livestreams on YouTube after verdict in trial, talks about doing 'God's work' - August 6 at 5:10 AM logoJury finds Shkreli guilty on 3 of 8 fraud charges - August 5 at 6:47 AM logoFormer drug company executive Martin Shkreli is convicted of fraud - August 5 at 6:47 AM logo'Pharma bro' Shkreli convicted of fraud in U.S. court, assails 'witch hunt' - August 5 at 6:47 AM logoSecurities experts chime in on Shkreli trial - August 4 at 7:46 AM logoShkreli Jury Ends Third Day of Deliberations Without a Verdict - August 2 at 9:05 PM logoJurors ask about fraud 'intent' at Martin Shkreli trial; 'pharma bro' reads Warren Buffett biography - August 2 at 7:22 AM logoJury in Martin Shkreli trial seeks clarity on 'fraudulent intent' - August 2 at 7:22 AM logoShkreli Jury Begins Deliberations in Brooklyn Fraud Trial - August 1 at 6:06 AM logoPharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case - August 1 at 6:06 AM logoShkreli closing arguments get heated: 'This is rich people B.S.' - July 29 at 6:56 AM logoShkreli Jury to Start Deliberations in Fraud Trial July 31 - July 29 at 6:56 AM logoMartin Shkreli gets smacked down on Twitter (again) after another lewd comment about reporter - July 29 at 6:56 AM logoWhat if Shkreli isn't convicted? It would be a major embarrassment, attorney says - July 29 at 6:56 AM logoJurors in Martin Shkreli case will begin deliberations Monday - July 29 at 6:56 AM logoProsecution and defense officially rest in Shkreli trial - July 28 at 7:28 AM logoGovernment's closing arguments highlight Shkreli's history of dishonesty - July 28 at 7:28 AM logoMartin Shkreli smirks, pulls faces during closing arguments by prosecutor at fraud trial - July 28 at 7:28 AM logoShkreli's lawyer uses potato chips, Borscht Belt jokes and jibes of 'rich people B.S.' in summation - July 28 at 7:28 AM logoShkreli portrayed both as liar, well-meaning as trial nears end - July 28 at 7:28 AM logo[$$] Prosecution in Martin Shkreli Case Makes Final Push - July 28 at 7:28 AM logoProsecution and defense rest in Shkreli trial - July 27 at 7:00 AM logoRetrophin to Report Second Quarter 2017 Financial Results - July 26 at 4:51 PM logoMartin Shkreli will not testify at his securities fraud trial, 'pharma bro' reveals - July 26 at 6:57 AM logoRetrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN - July 26 at 6:57 AM logoMartin Shkreli nastily berated lawyer, said his attorneys are 'lazy and stupid and paid too much' - July 26 at 6:57 AM logoProsecution and defense plan to rest in Martin Shkreli trial; closing arguments expected Thursday - July 26 at 6:57 AM logoMartin Shkreli quotes Jay-Z to justify why he will duck testifying at securities fraud trial - July 26 at 6:57 AM logo'Pharma bro' Martin Shkreli's securities fraud trial winds down - July 26 at 6:57 AM logo'Pharma Bro' Shkreli opts not to take witness stand as government calls last witness - July 26 at 6:57 AM



Retrophin (RTRX) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by Staff